American College of Clinical Pharmacy
      Search      Cart
         

SCHEDULE

BCPPS Clinical Session: Leveraging Biologics: Treatment Advances in the Management of Childhood-Onset Systemic Lupus Erythematosus

Monday, October 14, 2024 from 4:00 PM to 5:00 PM MST at Convention Center North Building / Meeting Room 122

Available for 1.00 hours of CPE credit
Activity Number: 0217-9999-24-069-L01
Activity Type: An Application-Based Activity

Treatment of childhood-onset systemic lupus erythematosus (cSLE) has been limited to traditional immunomodulators until the recent introduction of biologic therapy. Knowledge of these agents and their role in treatment is necessary for the pediatric pharmacist to develop an effective and safe therapeutic regimen and monitoring plan. This session will focus on the role of biologic therapy in the management of cSLE using interactive patient cases and in-depth evaluation of the current literature in order to equip the pediatric pharmacist with the necessary knowledge and tools to integrate into clinical practice.   

This activity is approved for Board Certified Pediatric Pharmacist (BCPPS) recertification credit. 

The BCPPS Clinical Sessions are part of the professional development program for the recertification of board-certified Pediatric Pharmacist by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCPPS recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the Clinical Sessions posttests will be available on December 18, 2024, at www.accp.com/myaccount to anyone who has purchased access to the BCPPS posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, October 15, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 16, 2025. 

Learning Objectives

1. Examine current non-biologic standards of care for childhood-onset systemic lupus erythematosus.

2. Evaluate current literature for the role and integration of biologic therapy in the management of childhood-onset systemic lupus erythematosus.

3. Develop strategies to manage biologic therapy for hospital and health-system formularies.

Ingrid Pan, Pharm.D., BCPPS
Speaker:Ingrid Pan, Pharm.D., BCPPS
Ambulatory Rheumatology Pharmacist
Children’s Hospital of Colorado
Aurora, Colorado
  View Biography

Cookies

This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.